Images
RTVE, the newspaper Heraldo de Aragón, and Diario Médico—the newspaper specialized in health—among other media, have echoed on a new algorithm, developed by researchers at IRB Barcelona in collaboration with the Centre for Genomic Regulation and the University of Radboud, that allows identification of those patients who are most likely to benefit from immunotherapy. Based on machine learning, the scientists have developed a tool that detects the genetic mutations that activate the immune system. This algorithm also identifies those people with certain hereditary diseases that would benefit from certain kinds of drug already on the market. The study was published in the journal Nature Genetics.
Link to RTVE
Link to Heraldo de Aragón
Link to Diario Médico
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
